Psychopharmacoepidemiology in Iceland: Effects of Regulations and New Medications

Overview

Journal Eur Arch Psychiatry Clin Neurosci

Specialties Neurology
Psychiatry

Date 1997 Jan 1

PMID 9177955

Authors

T Helgason

J K Bjornsson

T Zoega

H S Thorsteinsson

H Tomasson

Affiliations

Soon will be listed here.

Abstract

The sale of psychotropic medications in Iceland has waxed and waned during the past 20 years with approximately 5 years between peak and bottom quantities sold. Apparently, it has decreased following restrictions imposed by the public health authorities and increased again following the introduction of new drug. In order to study this further, all prescriptions for psychotropic medications to non-hospitalized inhabitants of the capital city (Reykjavík) and dispensed by pharmacists there during 1 month in 1984, 1989 and 1993 were analysed in order to estimate the 1-month prevalence of psychopharmacological use. The results support the hypothesis partly as prescriptions for tranquillizers decreased in 1989 as well as the amount of tranquillizers and hypnotics prescribed following new restrictions, whereas the prevalence odds ratio of obtaining prescriptions for hypnotics remained unchanged. The proportion of patients receiving excessive amounts of tranquillizers and/or hypnotics decreased. The prevalence of excessive use of these drugs (i.e. > 90 DDD/month) was 0.5% in 1993. In 1993 the prevalence of the use of antidepressants as well as the amount prescribed had increased substantially following the introduction of the new selective serotonin reuptake inhibitor medications. Thus, the prevalence of patients obtaining any psychotropic medication remained unchanged from 1984 to 1993.

References

. Practice guideline for major depressive disorder in adults. American Psychiatric Association. Am J Psychiatry. 1993; 150(4 Suppl):1-26. DOI: 10.1176/ajp.150.4.1. View

Cerbini S, Greco M, Lalli P, Santucci A, PITZURRA M . [Vaginal microscopic evidence in women with symptoms of genital infection]. Health Stat Nord Ctries. 1985; 36(1):77-84. View

Allgulander C . History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand. 1986; 73(5):465-78. DOI: 10.1111/j.1600-0447.1986.tb02713.x. View

Greenblatt D, Shader R, Abernethy D . Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983; 309(6):354-8. DOI: 10.1056/NEJM198308113090607. View

Hotopf M, Lewis G, Normand C . Are SSRIs a cost-effective alternative to tricyclics?. Br J Psychiatry. 1996; 168(4):404-9. DOI: 10.1192/bjp.168.4.404. View

Beardsley R, Gardocki G, Larson D, Hidalgo J . Prescribing of psychotropic medication by primary care physicians and psychiatrists. Arch Gen Psychiatry. 1988; 45(12):1117-9. DOI: 10.1001/archpsyc.1988.01800360065009. View

Isacson D, Haglund B . Psychotropic drug use in a Swedish community--the importance of demographic and socioeconomic factors. Soc Sci Med. 1988; 26(4):477-83. DOI: 10.1016/0277-9536(88)90317-6. View

Nolan L, OMalley K . Patients, prescribing, and benzodiazepines. Eur J Clin Pharmacol. 1988; 35(3):225-9. DOI: 10.1007/BF00558257. View

Weintraub M, Singh S, Byrne L, Maharaj K, Guttmacher L . Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991; 266(17):2392-7. View

10.

Covi L, Lipman R, Pattison J, DeRogatis L, Uhlenhuth E . Length of treatment with anxiolytic sedatives and response to their sudden withdrawal. Acta Psychiatr Scand. 1973; 49(1):51-64. DOI: 10.1111/j.1600-0447.1973.tb04398.x. View

11.

Petursson H, Lader M . Benzodiazepine dependence. Br J Addict. 1981; 76(2):133-45. DOI: 10.1111/j.1360-0443.1981.tb00218.x. View

12.

Shorr R, Fought R, Ray W . Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA. 1994; 271(5):358-62. View

13.

Fruensgaard K . Withdrawal psychosis: a study of 30 consecutive cases. Acta Psychiatr Scand. 1976; 53(2):105-18. DOI: 10.1111/j.1600-0447.1976.tb00065.x. View

14.

Olafsson O, Sigfusson S, Grimsson A . Control of addictive drugs in Iceland 1976--78. J Epidemiol Community Health. 1980; 34(4):305-8. PMC: 1052096. DOI: 10.1136/jech.34.4.305. View

15.

Goodnick P, Sandoval R . Psychotropic treatment of chronic fatigue syndrome and related disorders. J Clin Psychiatry. 1993; 54(1):13-20. View

16.

Joukamaa M, Sohlman B, Lehtinen V . The prescription of psychotropic drugs in primary health care. Acta Psychiatr Scand. 1995; 92(5):359-64. DOI: 10.1111/j.1600-0447.1995.tb09597.x. View

17.

Uhlenhuth E, Balter M, Mellinger G . Clinical variables in pharmacoepidemiology. J Psychiatr Res. 1993; 27 Suppl 1:89-95. DOI: 10.1016/0022-3956(93)90020-3. View

18.

Regier D, Boyd J, Burke Jr J, Rae D, MYERS J, Kramer M . One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988; 45(11):977-86. DOI: 10.1001/archpsyc.1988.01800350011002. View

19.

Soumerai S, Avorn J, Ross-Degnan D, Gortmaker S . Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. N Engl J Med. 1987; 317(9):550-6. DOI: 10.1056/NEJM198708273170906. View

20.

Mellinger G, Balter M, Uhlenhuth E . Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985; 42(3):225-32. DOI: 10.1001/archpsyc.1985.01790260019002. View